Press releases


Stein Ulve, the CEO of Eevia Health Plc, ("Eevia" or "The Company"), subscribed for 489 996 shares in the preferential rights issue, which Eevia concluded on November 17th. The equity issue was for 14 376 015 shares and was fully subscribed. Stein Ulve had 1 907 500 subscription rights, but he subscribed for 489 996 shares. Consequently, he was diluted under the flagging threshold of 10%.

Stein Ulve, who is a PDMR of the company, had 1 907 500 shares or 11,94% of the total outstanding shares before the rights issue. He subscribed for 489 996 shares and his new total is 2 397 496 shares. With the new total shares of 30 349 371, his holding will be 7,90% of the company's outstanding shares when the new shares have been registered with Finnish authorities. Registration is expected this week. Stein Ulve has no options or other financial instruments as part of any incentive system in Eevia. Stein Ulve has purchased and paid for all shares he holds in Eevia Health Oyj.

In the rights issue, also three board members subscribed for shares in the equity issue, without passing flagging thresholds.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          


Telephone: +358 400 22 5967 


Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.

To learn more, please visit or follow Eevia Health on LinkedIn @EeviaHealth. 

Files for download